Our latest insights
What We're Thinking
We’re wrapping up our Mix Tape mini-series by breaking down how to build Career Development tools that engage your team and boost retention. In this episode, Valerie is joined by Mix Talent's Head of HR, Daryl Neville, and our Director of Leadership & Culture, Sara Shondrick, PhD to discuss different types of training, how to assess training needs, and how to prioritize and work together to figure out strategies that bridge the gap between where you are and where you want to be.
With remote work taking over the international workforce, how does a company stay connected? Managing and engaging with a geographically diverse team happens every day at Mix Talent, so Valerie sits down with Todd Radloff, Head of Client Solutions and Delivery, as well as Patty Adams, Head of HR Consulting, to discuss Mix's approach and other helpful strategies for other organizations learning how to navigate remote teams.
In Part 2 of our miniseries featuring Mix Talent we dive into where our culture comes from: was it planned from the beginning or developed over time? Natalie sits down with our Head of Strategy K.C. McAllister and Head of Assessment & Consulting Chad Thompson for a little company and advice on how to develop a beneficial culture in your office!
In the first episode of our mini-series: The Secret's in the Mix, we are joined by two impactful leaders - Mickey Shimp, President of Mix Talent, and Jon DeWitt, Executive Coach at JS DeWitt and Associates - to dive into the topic of leadership, discussing why authentic and transparent leadership is imperative and how to invest in your people to build strong relationships with your teams.
After a robust and unprecedented 2021 in the life sciences industry, the positive momentum that began in 2020 flatlined in 2022. Layoffs are happening in waves across the industry, with 23 companies announcing layoffs in November alone, bringing the 2022 total to 119 companies. Similarly, fundraising has taken a hit. Industrywide, M&A volume is down 48% while deal valuations plunged 28% this year. While there is plenty of optimism that these trends are temporary — and PwC predicts there is a strong year ahead for M&A in the sector — there is no question the resetting of valuations is going to lead to some short-term pain.
Beyond the seasonal career reflections that happen around this time of year, it seems there’s also a new headline every week (if not every day) about layoffs and cuts being made across the pharma and biotech world – meaning there are a lot of people in the life sciences looking for their next opportunities. If you’re in that camp, I want to challenge you to consider your approach to what’s next.